Cargando…

DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors

Objective: Mcl-1 overexpression confers acquired resistance to Bcl-2 inhibitors in non-small cell lung cancer (NSCLC), but no direct Mcl-1 inhibitor is currently available for clinical use. Thus, novel therapeutic strategies are urgently needed to target Mcl-1 and sensitize the anti-NSCLC activity o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yangling, Zhou, Dongmei, Xu, Shuang, Rao, Mingjun, Zhang, Zuoyan, Wu, Linwen, Zhang, Chong, Lin, Nengming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309455/ https://www.ncbi.nlm.nih.gov/pubmed/32587776 http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0380

Ejemplares similares

Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
por: Li, Yangling, et al.
Publicado: (2022)

DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291
por: Li, Yang‐ling, et al.
Publicado: (2019)

Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics
por: Dalafave, D.S., et al.
Publicado: (2010)

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
por: Lee, Erinna F., et al.
Publicado: (2019)

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes
por: Seiller, Carolane, et al.
Publicado: (2020)

MiRNA-16-1 Suppresses Mcl-1 and Bcl-2 and Sensitizes Chronic Lymphocytic Leukemia Cells to BH3 Mimetic ABT-199
por: Ashofteh, Nooshin, et al.
Publicado: (2022)

Survival of midbrain dopamine neurons depends on the Bcl2 factor Mcl1
por: Robinson, Edward J., et al.
Publicado: (2018)

Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells
por: Chen, Hua, et al.
Publicado: (2017)

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo
por: Karpel-Massler, Georg, et al.
Publicado: (2015)

MCL-1–dependent leukemia cells are more sensitive to chemotherapy than BCL-2–dependent counterparts
por: Brunelle, Joslyn K., et al.
Publicado: (2009)

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X(L) expression
por: Yasuda, Yuto, et al.
Publicado: (2020)

Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
por: Shang, Enyuan, et al.
Publicado: (2020)

DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B
por: Yousefelahiyeh, Mina, et al.
Publicado: (2018)

Differential maturation and chaperone dependence of the paralogous protein kinases DYRK1A and DYRK1B
por: Papenfuss, Marco, et al.
Publicado: (2022)

The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2
Publicado: (1995)

Cyclic Marinopyrrole Derivatives as Disruptors of Mcl-1 and Bcl-x(L) Binding to Bim
por: Cheng, Chunwei, et al.
Publicado: (2014)

Combined reduction in the expression of MCL-1 and BCL-2 reduces organismal size in mice
por: Ke, Francine, et al.
Publicado: (2020)

Correction to: Survival of midbrain dopamine neurons depends on the Bcl2 factor Mcl1
por: Robinson, Edward J., et al.
Publicado: (2022)

Decreased IGF-1 level is associated with restrained amino acid metabolism in NSCLC with diabetes mellitus
por: Lv, Hehe, et al.
Publicado: (2022)

The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition
por: Peddaboina, Chander, et al.
Publicado: (2012)

Sensitivity of Cutaneous T-Cell Lymphoma Cells to the Mcl-1 Inhibitor S63845 Correlates with the Lack of Bcl-w Expression
por: Sumarni, Uly, et al.
Publicado: (2022)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis
por: Booher, Robert N., et al.
Publicado: (2014)

MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL
por: Vikström, Ingela B, et al.
Publicado: (2016)

Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1
por: Mena, Salvador, et al.
Publicado: (2012)

A novel de novo heterozygous DYRK1A mutation causes complete loss of DYRK1A function and developmental delay
por: Lee, Kyu-Sun, et al.
Publicado: (2020)

Selective Affimers Recognise the BCL‐2 Family Proteins BCL‐x(L) and MCL‐1 through Noncanonical Structural Motifs
por: Miles, Jennifer A., et al.
Publicado: (2020)

Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies
por: Melvold, Katrine, et al.
Publicado: (2021)

The MCL-1 BH3 Helix is an Exclusive MCL-1 inhibitor and Apoptosis Sensitizer
por: Stewart, Michelle L., et al.
Publicado: (2010)

Mutational analysis of two residues in the DYRK homology box of the protein kinase DYRK1A
por: Widowati, Esti Wahyu, et al.
Publicado: (2018)

Regulation of anti-apoptotic Bcl-2 family protein Mcl-1 by S6 kinase 2
por: Basu, Alakananda, et al.
Publicado: (2017)

Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma
por: Mukherjee, Nabanita, et al.
Publicado: (2020)

Computational design of an apoptogenic protein that binds BCL-xL and MCL-1 simultaneously and potently
por: Kim, Seonghoon, et al.
Publicado: (2022)

Simultaneous Inhibition of Mcl-1 and Bcl-2 Induces Synergistic Cell Death in Hepatocellular Carcinoma
por: Michalski, Marlen, et al.
Publicado: (2023)

MiRNA-Mediated Knock-Down of Bcl-2 and Mcl-1 Increases Fludarabine-Sensitivity in CLL-CII Cells
por: Ashofteh, Nooshin, et al.
Publicado: (2021)

Bak and Bcl-xL Participate in Regulating Sensitivity of Solid Tumor Derived Cell Lines to Mcl-1 Inhibitors
por: Senichkin, Viacheslav V., et al.
Publicado: (2021)

Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines
por: Abdul Rahman, Siti Fairus, et al.
Publicado: (2020)

Securidaca–saponins are natural inhibitors of AKT, MCL-1, and BCL2L1 in cervical cancer cells
por: Obasi, Titus Chukwuemeka, et al.
Publicado: (2018)

Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression
por: Xu, Jianliang, et al.
Publicado: (2019)

DYRK1A suppression attenuates HIF-1α accumulation and enhances the anti-liver cancer effects of regorafenib and sorafenib under hypoxic conditions
por: Zhang, Chong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3kars69bointdhr1rlvriul0lg